SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Celularity Inc.

(Name of Issuer)

Class A Common Stock, Par Value $0.0001 Per Share

(Title of Class of Securities)

151190204

(CUSIP Number)

Philip & Daniele Barach Family
Philip A. Barach, Daniele Barach, 434 Surfview Drive
Pacific Palisades, CA, 90272
(818) 694-0182

Jay Coogan, Esquire
Pierson Ferdinand LLP, 1650 Market Street, 36th Floor
Philadelphia, PA, 19103
(267) 265-8598

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/20/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

151190204

Name of reporting person

PHILIP & DANIELE BARACH FAMILY TRUST

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,558,665.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,558,665.00

Aggregate amount beneficially owned by each reporting person

7,558,665.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

20.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP Number(s):

151190204

Name of reporting person

PHILIP A. BARACH

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,558,665.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,558,665.00

Aggregate amount beneficially owned by each reporting person

7,558,665.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

20.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP Number(s):

151190204

Name of reporting person

DANIELE BARACH

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,558,665.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,558,665.00

Aggregate amount beneficially owned by each reporting person

7,558,665.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

20.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Class A Common Stock, Par Value $0.0001 Per Share

(b)

Name of Issuer:

Celularity Inc.

(c)

Address of Issuer's Principal Executive Offices:

170 Park Ave, Florham Park, NEW JERSEY , 07932.

Item 1 Comment:

This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on April 3, 2026 (the "Original Schedule 13D") by Philip & Daniele Barach Family Trust (the "Trust"), Philip A. Barach and Daniele Barach (each, a "Reporting Person" and collectively, the "Reporting Persons") relating to the Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of Celularity Inc. (the "Company"). Except as specifically amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. Capitalized terms used herein without definition have the meanings ascribed to them in the Original Schedule 13D.

Item 3.

Source and Amount of Funds or Other Consideration

On December 19, 2025, the Company and the Trust engaged in two financing transactions (collectively, the "Financing") pursuant to which the Company issued to the Trust a senior secured promissory note in the principal amount of $7,000,000 (the "Senior Note") and a convertible secured promissory note in the aggregate principal amount of $3,000,000 (the "Convertible Note" and, together with the Senior Note, the "Notes") and, in connection with the issuance of the Notes, issued to the Trust five-year warrants to purchase an aggregate of 3,707,457 shares of Class A Common Stock which are exercisable beginning on June 19, 2026 and have an exercise price of $2.00 per share, subject to adjustment as set forth therein. Pursuant to the Convertible Note Purchase Agreement dated as of December 19, 2025 by and between the Company and the Trust under the terms of which the Company issued the Convertible Note to the Trust (the "Convertible Note Purchase Agreement"), the Trust also has the right to purchase additional convertible notes in up to two tranches of $1,000,000 each, containing terms identical to and issuable upon the same terms and conditions as the Convertible Note (each, an "Additional Convertible Note" and, together with the Convertible Note, the "Convertible Notes"). All of the Convertible Notes are or will be convertible into shares of Class A Common Stock at a conversion price of $1.66 per share, subject to adjustment as provided therein. If the Additional Convertible Notes in the aggregate principal amount of up to $2,000,000 are issued at the election of the Trust, under the terms of the Convertible Note Purchase Agreement, the Company will issue to the Trust warrants to purchase an additional 839,160 shares of Class A Common Stock on terms identical to the warrants issued on December 19, 2025 (together with the warrants issued on December 19, 2025, the "Warrants"). The number of shares of Class A Common Stock reported as beneficially owned herein represents (i) 3,012,048 shares of Class A Common Stock issuable upon conversion of $5,000,000 in aggregate principal amount of Convertible Notes (assuming the issuance of Additional Convertible Notes in two tranches of $1,000,000 each at the election of the Trust) at the conversion price of $1.66 per share, (ii) 3,707,457 shares of Class A Common Stock issuable upon exercise of the Warrants issued on December 19, 2025, which become exercisable on June 19, 2026 and are thus deemed beneficially owned herein for the first time as of April 20, 2026, and (iii) 839,160 shares of Class A Common Stock issuable upon exercise of additional Warrants to potentially be issued in connection with the issuance of up to $2,000,000 in Additional Convertible Notes at the election of the Trust, which become exercisable on June 19, 2026 and are thus deemed beneficially owned herein for the first time as of April 20, 2026, for a total of 7,558,665 shares of Class A Common Stock. The source of funds for the Trust to purchase the Notes in the aggregate principal amount of $10,000,000 was cash held by the Trust at the time of the Financing. It is anticipated that if the Trust purchases any Additional Convertible Notes or exercises any of the Warrants, the source of funds for the Trust to purchase the Additional Convertible Notes or to exercise such Warrants will be cash held by the Trust at the time of such purchase. No additional consideration will be paid upon any conversion of the Convertible Notes into shares of Class A Common Stock or upon the issuance of any additional Warrants.

Item 5.

Interest in Securities of the Issuer

(a)

The information contained on the cover pages to this Amendment and the information set forth or incorporated in Items 2, 4 and 6 of the Original Schedule 13D and Item 3 of this Amendment are incorporated herein by reference. Each of the Reporting Persons beneficially owns 7,558,665 shares of Class A Common Stock, which number includes (i) 3,012,048 shares of Class A Common Stock issuable upon the conversion of $5,000,000 in aggregate principal amount of Convertible Notes (including $2,000,000 in Additional Convertible Notes that the Trust has the present, discretionary right to purchase under the Convertible Note Purchase Agreement) at a conversion price of $1.66 per share, and (ii) 4,546,617 shares of Class A Common Stock issuable upon the exercise of all Warrants at an exercise price of $2.00 per share (including 839,160 shares issuable upon the exercise of additional Warrants that the Company is contractually obligated to issue to the Trust upon the Trust's purchase of Additional Convertible Notes). The shares described in clauses (i) and (ii) are deemed beneficially owned by the Reporting Persons pursuant to Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended, because the Trust has the right to acquire beneficial ownership of such shares within 60 days of April 20, 2026, through a chain of rights entirely within the Trust's control, including (a) the Trust's discretionary right to purchase the Additional Convertible Notes at any time under the Convertible Note Purchase Agreement, (b) the Company's contractual obligation to issue the additional Warrants upon such purchase, (c) the Trust's right to convert all Convertible Notes into shares of Class A Common Stock at any time and (d) the exercisability of all Warrants beginning on June 19, 2026, which is within 60 days of April 20, 2026. The shares of Class A Common Stock beneficially owned by the Reporting Persons represents 20.1% of the shares of Class A Common Stock issued and outstanding, which calculation is based on 28,478,880 shares of Class A Common Stock of the Company issued and outstanding as of December 19, 2025, which was the date of the closing of the Financing. Each of Mr. Barach and Ms. Barach disclaims beneficial ownership of the shares of Class A Common Stock owned by the Trust, except to the extent of their pecuniary interest therein.

(b)

The information contained on the cover pages to this Amendment and the information set forth or incorporated in Items 2, 4 and 6 of the Original Schedule 13D and Item 3 of this Amendment are incorporated herein by reference. None of the Reporting Persons has the sole power to vote or to direct the vote, or the sole power to dispose or to direct the disposition of, any of the shares of Class A Common Stock owned by such Reporting Person. Each Reporting Person shares with the other Reporting Persons the power to vote or to direct the vote, or the power to dispose or to direct the disposition of, all 7,558,665 shares of Class A Common Stock owned by the Reporting Persons.

(c)

None of the Reporting Persons had any transactions in the Class A Common Stock (or securities convertible into or exercisable for shares of Class A Common Stock) during the past 60 days, except as described and referenced in Item 3 of this Amendment. There have been no acquisitions or dispositions of Class A Common Stock by the Reporting Persons since December 19, 2025, other than the Financing described in Item 3.

(d)

None.

(e)

Not applicable.

Item 7.

Material to be Filed as Exhibits.

1 Joint Filing Agreement, dated as of April 21, 2026, by and among Philip & Daniele Barach Family Trust, Philip A. Barach and Daniele Barach.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PHILIP & DANIELE BARACH FAMILY TRUST

Signature:	/s/ Philip A. Barach
Name/Title:	Philip A. Barach, Trustee of the Trust
Date:	04/22/2026

PHILIP A. BARACH

Signature:	/s/ Philip A. Barach
Name/Title:	Philip A. Barach
Date:	04/22/2026

DANIELE BARACH

Signature:	/s/ Daniele Barach
Name/Title:	Daniele Barach
Date:	04/22/2026

Amendment: SEC Form SCHEDULE 13D/A filed by Celularity Inc.